期刊文献+

来那度胺联合地塞米松治疗老年复发难治性多发性骨髓瘤的疗效观察 被引量:5

下载PDF
导出
摘要 目的探究老年复发难治性多发性骨髓瘤应用来那度胺联合地塞米松治疗的临床疗效。方法随机选择42例在我院接受多发性骨髓瘤诊治的患者,给予所有患者常规剂量的地塞米松联合来那度胺治疗。观察所有患者的治疗效果。结果 22例患者完全缓解,14例患者部分缓解,6例患者治疗无效,治疗有效率为85.71%。全部研究对象均出现乏力现象且均未超出患者耐受度。血小板减少发生率为14.29%,白细胞减少发生率为19.05%,40.48%患者发生轻度周围神经病变,没有患者发生深静脉血栓。结论复发难治性多发性骨髓瘤应用来那度胺联合地塞米松治疗能够取得理想的临床疗效,具有较高的应用安全性。
作者 刘荟敏
出处 《临床检验杂志(电子版)》 2017年第4期699-700,共2页 Clinical Laboratory Journal(Electronic Edition)
  • 相关文献

参考文献4

二级参考文献44

  • 1吴泰相,刘关键.隐蔽分组(分配隐藏)和盲法的概念、实施与报告[J].中国循证医学杂志,2007,7(3):222-225. 被引量:174
  • 2Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med, 2004, 351: 1860-1873.
  • 3Rajkumar SV, Kyle RA. Multiple myeloma: Diagnosis and treatment. Mayo Clin Proc, 2005, 80: 1371-1382.
  • 4Richardson P, Mitsiades C, Schlossman R, et al. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program, 2007: 317-323.
  • 5Hideshima T, Raje N, Richardson PG, et al. A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag, 2008, 4(1): 129-136.
  • 6Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 2002, 100: 3063- 3067.
  • 7Richardson P, Jagannath S, Hussein M, et al. A multicenter, singlearm,open-label study to evaluate the efficacy and safety of singleagent lenalidomide in patients with relapsed and refractory multiple myeloma; preliminary results. Blood, 2005, 106: 449a.
  • 8Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, 108: 3458-3464.
  • 9Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. N Engl J Med, 2007, 357: 2133-2142.
  • 10Dimopoulos MA, Spencer A, Attal M, et al. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. N Engl J Med, 2007, 357: 2123-2132.

共引文献22

同被引文献35

引证文献5

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部